Comparing antibody and small-molecule therapies for cancer
Top Cited Papers
- 1 September 2006
- journal article
- review article
- Published by Springer Nature in Nature Reviews Cancer
- Vol. 6 (9) , 714-727
- https://doi.org/10.1038/nrc1913
Abstract
The 'magic bullet' concept of specifically targeting cancer cells at the same time as sparing normal tissues is now proven, as several monoclonal antibodies and targeted small-molecule compounds have been approved for cancer treatment. Both antibodies and small-molecule compounds are therefore promising tools for target-protein-based cancer therapy. We discuss and compare the distinctive properties of these two therapeutic strategies so as to provide a better view for the development of new drugs and the future direction of cancer therapy.Keywords
This publication has 141 references indexed in Scilit:
- A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin SignalingCell, 2006
- Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)The Lancet, 2005
- Dynamics of chronic myeloid leukaemiaNature, 2005
- Structural basis for inhibition of the epidermal growth factor receptor by cetuximabPublished by Elsevier ,2005
- Tumour stem cells and drug resistanceNature Reviews Cancer, 2005
- Targeted cancer therapyNature, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complexCancer Cell, 2004
- Structure of the extracellular region of HER2 alone and in complex with the Herceptin FabNature, 2003
- The Hallmarks of CancerCell, 2000